Communiqués TScan Therapeutics, Inc.

Actions

TCRX

US89854M1018

Recherche biotechnologique et médicale

Temps Différé Nasdaq Autres places de cotation 20:24:39 30/07/2026			Varia. 5j.	Varia. 1 janv.
0,7604 ^USD	+2,54%		-10,16%	-23,96%

29/07	TScan Therapeutics traite un premier patient dans l'essai de phase 3 ALLOHA-2 évaluant le TSC-101 pour les hémopathies malignes	CI
22/06	TScan Therapeutics présente les premières données de la cohorte C de l'étude de phase 1 ALLOHA évaluant TSC-101 chez des patients atteints d'hémopathies malignes sous transplantation de cellules souches hématopoïétiques allogéniques	CI

Communiqués

15:48	TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies	AQ
29/07	TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies	GL
29/07	TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies	AQ
24/06	TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference	GL
24/06	TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference	AQ
22/06	TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation	GL
03/06	Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies	BU
06/05	TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update	GL
27/04	TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting	GL
08/04	TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference	GL
08/04	TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference	AQ
19/03	Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care	PR
04/03	TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update	GL
26/02	TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03	GL
25/02	TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference	GL
08/12	TScan Therapeutics : Company ASH KOL Presentation – December 2025	PU
08/12	TScan Therapeutics : ASH 2025 Virtual KOL Presentation	PU
06/12	TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition	GL
03/12	TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities	GL
12/11	TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update	GL
05/11	TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference	GL
03/11	TScan Therapeutics : Update Call November 2025	PU
03/11	TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027	GL
17/09/25	TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025	GL
03/09/25	TScan Therapeutics to Participate in Upcoming Investor Conferences	GL